Why Bristol-Myers Squibb (BMY) Is Back In The Spotlight

Bristol-Myers Squibb (BMY) is back in focus after reporting positive Phase 3 data for two late stage drugs: RYZ101 in gastroenteropancreatic neuroendocrine tumors and admilparant in idiopathic pulmonary fibrosis.

The recent clinical wins land at an awkward moment for Bristol-Myers Squibb investors, with the share price at US$56.67 after a 30 day share price return that is down 10.95% and a 7 day share price return that is down 4.90%. This is occurring even though the year to date share price return is up 6.00% and the 1 year total shareholder return is up 35.14%. This mix points to strong longer term wealth creation but fading short term momentum as the market reassesses risk and future payoff from the pipeline after a busy run of trial readouts, product approvals and partnership headlines.

Spot opportunities that rhyme with the Bristol-Myers Squibb story by scanning our hand picked list of 32 high quality undervalued stocks that pair solid cash flows with disciplined balance sheets.

Bristol-Myers Squibb clearly has depth in its product portfolio and late stage pipeline. After the recent share price pullback, the real question is whether that strength is already reflected in the US$56.67 quote or not.

Most Popular Narrative: 15% Undervalued

The most followed Bristol-Myers Squibb narrative points to a fair value of about $66.71, which sits above the recent $56.67 close and leans heavily on how the current growth portfolio and cash generation offset upcoming patent pressures.

Ongoing shift in Bristol-Myers Squibb’s revenue mix toward its growth portfolio, which reached $7.6b in Q2 2026 and nearly 60% of total sales, supports the view that new products can increasingly offset legacy erosion and underpin future revenue and earnings.

See why 229 investors see Bristol-Myers Squibb as 15% undervalued.

Result: Fair Value of $66.71 (UNDERVALUED)

Still, the Bristol-Myers Squibb story could be shaken if Eliquis faces faster erosion after patent expiry or if safety concerns slow key late stage approvals.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Next Steps

If this mix of optimism and concern around Bristol-Myers Squibb feels familiar, treat it as your cue to move quickly and check the underlying numbers yourself. The fastest way to pressure test both sides of the story is to map out the 4 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb has sharpened your focus on quality, now is the moment to widen your lens and look for other credible opportunities using targeted screeners.

• Target reliable cash generators by using the 32 high quality undervalued stocks that blend strong balance sheets with disciplined cash flows and more measured pricing.
• Prioritize resilience by scanning the 32 resilient stocks with low risk scores so you can focus on businesses with sturdier financial and risk profiles.
• Search for tomorrow’s potential leaders with the 20 high quality undiscovered gems and identify strong fundamentals before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com